loading...| Preferred Name |
ticagrelor |
|
| Synonyms |
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol C23H28F2N6O4S AZD 6140 Brilinta ticagrelor AZD6140 AZD-6140 (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
|
| ID |
http://purl.obolibrary.org/obo/CHEBI_68558 |
|
| AHFScode |
20:12:18 |
|
| ATCCode |
B01AC24 |
|
| CASRN |
274693-27-5 |
|
| DBBrand |
possia brilique |
|
| DBSynonym |
azd6140 |
|
| Definition |
A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome. Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. |
|
| has pharmacological target | ||
| has role | ||
| InChI |
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1 |
|
| InChIKey |
InChIKey=OEKWJQXRCDYSHL-FNOIDJSQSA-N |
|
| inhibits | ||
| is metabolised by | ||
| is transported by | ||
| label |
ticagrelor |
|
| may interact with |
http://purl.obolibrary.org/obo/CHEBI_9150 http://purl.obolibrary.org/obo/CHEBI_40303 |
|
| prefixIRI |
obo2:CHEBI_68558 |
|
| prefLabel |
ticagrelor |
|
| SMILES |
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1 CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1 |
|
| Synonym |
(1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol C23H28F2N6O4S AZD 6140 Brilinta ticagrelor AZD6140 AZD-6140 (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol |
|
| xref |
CASRN:274693-27-5 Wikipedia:http://en.wikipedia.org/wiki/Ticagrelor Drugs.com:http://www.drugs.com/cdi/ticagrelor.html RxList:http://www.rxlist.com/brilinta-drug.htm HMDB:HMDB15702 National Drug Code Directory:0186-0777-08 KEGG DRUG:D09017 Patent:WO2012085665 Reaxys:15468079 CiteXplore:22991347 ChEMBL:516772 |
|
| subClassOf |